文献速递肿瘤 PET/CT甲状腺核医学

[18F]FDG-PET/CT诊断复发性乳腺癌的获益与危害:一项前瞻性临床研究

Benefits and harms of implementing [18F]FDG-PET/CT for diagnosing recurrent breast cancer: a prospective clinical study.
PubMed 文献 · EJNMMI Res · 2021-09-22

该前瞻性研究纳入225例临床疑似远处复发性乳腺癌女性,评估[18F]FDG-PET/CT作为独立检查的诊断准确性及偶发发现带来的临床影响。结果显示其对远处转移的诊断敏感性为1.00、特异性为0.88,阳性后验概率达85%;20.4%患者检出可疑恶性偶发发现,最终确诊9例同步癌(4.0%),但16.4%患者因假阳性偶发发现接受进一步检查。

要点

  • [18F]FDG-PET/CT诊断远处转移敏感性1.00、特异性0.88,阴性可排除远处转移。
  • 阳性后验概率85%,但20.4%患者检出可疑恶性偶发发现,最终确诊同步癌仅4.0%。
  • 16.4%患者因假阳性偶发发现接受进一步检查,主要涉及结肠和甲状腺。

核心结论

  • [18F]FDG-PET/CT对临床疑似复发性乳腺癌女性远处转移诊断准确性高,阴性结果可排除远处转移。
  • 约五分之一因偶发发现接受检查的患者最终诊断为临床相关疾病。
  • 六分之一女性因假阳性偶发发现接受进一步检查,需权衡其与高诊断准确性之间的利弊。

研究设计与样本

  • 前瞻性临床研究,2017年9月至2019年8月纳入225例临床疑似远处复发性乳腺癌女性。
  • 行[18F]FDG-PET/CT检查,登记偶发良恶性发现及后续检查、并发症和最终诊断。
  • 以活检和随访为参考标准,分析[18F]FDG-PET/CT作为独立检查的诊断准确性。

主要发现

  • [18F]FDG-PET/CT报告72/225例(32.0%)存在乳腺癌转移,活检证实52/225例(23.1%)。
  • 疑似转移癌和偶发恶性肿瘤的阳性测验验前概率/后验概率分别为27%/85%和4%/20%。
  • 46/225例(20.4%)报告可疑恶性偶发发现,最终检出9/225例(4.0%)同步癌,来源包括肺、甲状腺、皮肤、胰腺、腹膜、乳腺、肾、恶性黑色素瘤及血液系统肿瘤。
  • 37/225例(16.4%)假阳性偶发恶性发现接受检查,主要位于结肠(n=12)和甲状腺(n=12)。

关键数值与推荐

  • 诊断远处转移的敏感性1.00(0.93-1.0),特异性0.88(0.82-0.92),AUC-ROC 0.98(95% CI 0.97-0.99)。

临床怎么用

  • 对临床疑似远处复发性乳腺癌女性,[18F]FDG-PET/CT可作为高准确性独立检查,阴性结果有助于排除远处转移。
  • 阳性结果后验概率高,但需注意偶发发现中假阳性比例较高,进一步检查决策应结合原始影像与临床情况权衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography ([18F]FDG-PET/CT) has been implemented sporadically in hospital settings as the standard of care examination for recurrent breast cancer. We aimed to explore the clinical impact of implementing [18F]FDG-PET/CT for patients with clinically suspected recurrent breast cancer and validate the diagnostic accuracy. METHODS: Women with suspected distant recurrent breast cancer were prospectively enrolled in the study between September 2017 and August 2019. [18F]FDG-PET/CT was performed, and the appearance of incidental benign and malignant findings was registered. Additional examinations, complications, and the final diagnosis were registered to reflect the clinical consequence of such findings. The diagnostic accuracy of [18F]FDG-PET/CT as a stand-alone examination was analyzed. Biopsy and follow-up were used as a reference standard. RESULTS: [18F]FDG-PET/CT reported breast cancer metastases in 72 of 225 women (32.0%), and metastases were verified by biopsy in 52 (52/225, 23.1%). Prior probability and posterior probability of a positive test for suspected metastatic cancer and incidental malignancies were 27%/85% and 4%/20%, respectively. Suspected malignant incidental findings were reported in 46 patients (46/225, 20.4%), leading to further examinations and final detection of nine synchronous cancers (9/225, 4.0%). These cancers originated from the lung, thyroid, skin, pancreas, peritoneum, breast, kidney, one was malignant melanoma, and one was hematological cancer. False-positive incidental malignant findings were examined in 37/225 patients (16.4%), mainly in the colon (n = 12) and thyroid gland (n = 12). Ten incidental findings suspicious for benign disease were suggested by [18F]FDG-PET/CT, and further examinations resulted in the detection of three benign conditions requiring treatment. Sensitivity, specificity, and AUC-ROC for diagnosing distant metastases were 1.00 (0.93-1.0), 0.88 (0.82-0.92), and 0.98 (95% CI 0.97-0.99), respectively. CONCLUSION: [18F]FDG-PET/CT provided a high posterior probability of positive test, and a negative test was able to rule out distant metastases in women with clinically suspected recurrent breast cancer. One-fifth of patients examined for incidental findings detected on [18F]FDG-PET/CT were diagnosed with clinically relevant conditions. Further examinations of false-positive incidental findings in one of six women should be weighed against the high accuracy for diagnosing metastatic breast cancer. Trial registration Clinical.Trials.gov. NCT03358589. Registered 30 November 2017-Retrospectively registered, http://www.ClinicalTrials.gov.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Vogsen M, Jensen JD, Gerke O, et al. Benefits and harms of implementing [18F]FDG-PET/CT for diagnosing recurrent breast cancer: a prospective clinical study. EJNMMI Res. 2021. PMID: 34553294. doi:10.1186/s13550-021-00833-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。